GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aprinoia Therapeutics Inc (NAS:APRI) » Definitions » Degree of Financial Leverage

Aprinoia Therapeutics (Aprinoia Therapeutics) Degree of Financial Leverage : 0.00 (As of Jun. 2023)


View and export this data going back to 2050. Start your Free Trial

What is Aprinoia Therapeutics Degree of Financial Leverage?

Degree of Financial Leverage (DFL) measures the percentage change in EPS for a unit change in Earnings Before Interest and Taxes (EBIT). Aprinoia Therapeutics does not have enough data to calculate Degree of Financial Leverage.


Aprinoia Therapeutics Degree of Financial Leverage Historical Data

The historical data trend for Aprinoia Therapeutics's Degree of Financial Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aprinoia Therapeutics Degree of Financial Leverage Chart

Aprinoia Therapeutics Annual Data
Trend Dec21 Dec22
Degree of Financial Leverage
- -

Aprinoia Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23
Degree of Financial Leverage - - - -

Competitive Comparison of Aprinoia Therapeutics's Degree of Financial Leverage

For the Biotechnology subindustry, Aprinoia Therapeutics's Degree of Financial Leverage, along with its competitors' market caps and Degree of Financial Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aprinoia Therapeutics's Degree of Financial Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aprinoia Therapeutics's Degree of Financial Leverage distribution charts can be found below:

* The bar in red indicates where Aprinoia Therapeutics's Degree of Financial Leverage falls into.



Aprinoia Therapeutics Degree of Financial Leverage Calculation

Aprinoia Therapeutics's Degree of Financial Leverage for the quarter that ended in Jun. 2023 is calculated as:

Degree of Financial Leverage=% Change in Earnings per Share (Diluted)**/% Change in EBIT
=( -0.781 (Jun. 2023) / (Jun. 2022) - 1 )/( -20.178 (Jun. 2023) / (Jun. 2022) - 1 )
=/
=N/A***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EPS and EBIT was used to calculate Degree of Financial Leverage.
*** Please be aware that the Degree of Financial Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Aprinoia Therapeutics  (NAS:APRI) Degree of Financial Leverage Explanation

Degree of Financial Leverage (DFL) is a leverage ratio that measures the sensitivity of a company’s Earnings per Share (EPS) to fluctuations in its operating income, also referred to as Earnings Before Interest and Taxes (EBIT), resulting from adjustments in its capital structure. DFL is an essential tool for companies to assess the appropriate level of debt or financial leverage in their capital structure. When EBIT remains relatively stable, it results in stable earnings and earnings per share. In such cases, the company may consider taking on substantial debt. However, for companies operating in industries with significant fluctuations in EBIT, it is advisable to keep debt at a manageable level.

The higher Degree of Financial Leverage, the more volatile earnings will be. Because interest is a fixed expense, leverage can amplify earnings and EPS. This is beneficial when EBIT is growing, but it can become problematic in tough economic conditions when EBIT is under pressure.

Be Aware

The use of financial leverage varies across different industries and business sectors, and the application of Degree of Financial Leverage (DFL) should be adjusted accordingly.


Aprinoia Therapeutics Degree of Financial Leverage Related Terms

Thank you for viewing the detailed overview of Aprinoia Therapeutics's Degree of Financial Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Aprinoia Therapeutics (Aprinoia Therapeutics) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
Website
Aprinoia Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in protecting patients' brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics. Neurodegenerative diseases are relentless and largely fatal, resulting from progressive loss of nerve cells in the brain and, depending on the specific disorders, can affect a broad range of cognitive, behavioral, and motor functions, such as memory, thinking, speaking, walking, and breathing. It is developing several different diagnostic and therapeutic platforms such as abnormal protein aggregates of tau and alpha synuclein ("?-Syn") that are toxic to brain cells.

Aprinoia Therapeutics (Aprinoia Therapeutics) Headlines

No Headlines